argenx (NASDAQ:ARGX) Price Target Raised to $547.00

argenx (NASDAQ:ARGX) had its price objective boosted by Wells Fargo & Company from $543.00 to $547.00 in a report released on Friday, Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other equities analysts also recently issued reports about the company. Stifel Nicolaus raised their price target on argenx from $485.00 to $500.00 and gave the stock a buy rating in a research note on Monday, June 24th. JPMorgan Chase & Co. dropped their price target on argenx from $560.00 to $500.00 and set an overweight rating on the stock in a research note on Monday, May 13th. Morgan Stanley dropped their price target on argenx from $515.00 to $510.00 and set an overweight rating on the stock in a research note on Tuesday, May 28th. HC Wainwright raised their price target on argenx from $504.00 to $533.00 and gave the stock a buy rating in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft upgraded argenx from a hold rating to a buy rating in a research note on Thursday. Three equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, argenx presently has a consensus rating of Moderate Buy and an average price target of $539.05.

argenx Trading Up 1.7 %

ARGX stock opened at $494.46 on Friday. The stock has a market capitalization of $29.39 billion, a PE ratio of -87.36 and a beta of 0.64. argenx has a 12-month low of $327.73 and a 12-month high of $532.59. The stock’s 50 day simple moving average is $415.63 and its 200 day simple moving average is $394.89.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $1.34. The business had revenue of $489.43 million for the quarter, compared to analysts’ expectations of $436.66 million. argenx had a negative return on equity of 9.97% and a negative net margin of 12.31%. During the same period in the prior year, the firm posted ($1.69) EPS. On average, research analysts predict that argenx will post -2.59 earnings per share for the current year.

Institutional Investors Weigh In On argenx

Several large investors have recently made changes to their positions in the company. Lindbrook Capital LLC increased its holdings in shares of argenx by 23.1% in the first quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock worth $78,000 after purchasing an additional 37 shares during the last quarter. Wahed Invest LLC increased its holdings in shares of argenx by 9.6% in the fourth quarter. Wahed Invest LLC now owns 457 shares of the company’s stock worth $174,000 after purchasing an additional 40 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after purchasing an additional 40 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of argenx by 2.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 1,530 shares of the company’s stock worth $582,000 after purchasing an additional 41 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in shares of argenx by 3.1% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 1,428 shares of the company’s stock worth $543,000 after purchasing an additional 43 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.